

A.

In vivo model of acquired resistance to fluvastatin






Fig. 1: (A). Schematic showing the schedule of drug treatment in SV40C3 TAg mouse model of breast cancer progression and the end point analyses. *HR* hormone receptor. Fluvastatin treatment reduces tumor incidence, delays onset of tumor, and inhibits tumor growth in the SV40C3 TAg mouse model of breast cancer progression. **(B).** Fluvastatin treatment (10 mg/kg/day) for 16 weeks inhibited the percentage of mice that developed mammary tumors as determined by the macroscopic lesions at the time of necropsy at 22 weeks of age **(C).** and the average number of tumors per mouse relative to the vehicle control group after 16 weeks of treatment. **(D).** and delayed the average age at which tumors appear, as shown here as the % incidence of palpable tumor bearing mice during study (12 week of age to 21-week age), relative to the vehicle control group. * $p < 0.05$


B.



C.



D.



Gene signature of acquired resistance to statins

Statin resistance signature derived from in vitro model

In vivo validation




Fig. 2: Acquired resistance to fluvastatin causes restorative metabolic reprogramming. **(A & B).** Heatmap showing the genes that map to steroid biosynthesis and terpenoid backbone biosynthesis in the fluvastatin resistant MCF10.AT-R cells, including ACAT1 (SOAT1) and ACAT2. **(C).** Bar diagrams show qPCR validation where over expression of genes (including ACAT1/ SOAT1 and ACAT2 statin resistance gene panel) correlates tumor outcome in fluvastatin treated SV40C3TAg mice. The Y axis depicts the fold changes of average gene expression that was calculated by using the $\Delta\Delta C_t$ method after normalizing with ribosomal protein L19. Red color in bar diagram represents the fold changes were significant and gray represents non-significant (NS) changes at an FDR of < 5%



A.**B.**

Fig. 3: Fluvastatin inhibits colonization ability and proliferation of breast preneoplastic cells. **(A).** Clonogenic survival assay showing crystal violet-stained colonies formed by preneoplastic MCF10.AT1 and MCF10.DCIS cells after 12 days of treatment with fluvastatin or vehicle control. **(B).** Quantification of colonies formed by MCF10.DCIS cells treated with fluvastatin or vehicle control. Values represent number of colonies (%) ± SEM. * $p < 0.001$.